My Treatment Approach: HER2+ Breast Cancer - Episode 3

First-Line HER2+ Metastatic Breast Cancer Trials in Focus

, ,

Heather McArthur, MD, emphasizes the influence of recent and ongoing clinical trials, specifically DESTINY-Breast09 and HER2CLIMB-05, in steering the treatment paradigm in 1st-line HER2-positive metastatic breast cancer.

EP. 1: The Role of HER2 in Breast Cancer and Treatment Goals for HER+ Metastatic Breast Cancer Patients
EP. 2: Evolution of the HER2+ Metastatic Breast Cancer Treatment Landscape
Now Viewing
EP. 3: First-Line HER2+ Metastatic Breast Cancer Trials in Focus
EP. 4: Case Study: Treatment Sequencing for a 62 Year Old Woman with HER2+ Metastatic Breast Cancer After Progression on T-DXd
EP. 5: Evidence-Based Sequencing for HER2+ mBC After Progression: Clinical Trial Data and NCCN Guideline Updates
EP. 6: Managing Adverse Events and Toxicities HER2+ Metastatic Breast Cancer
EP. 7: TKI Regimens and Other Novel Approaches in Later Line Treatment of HER2+ mBC Setting
EP. 8: Case Study of a 54-Year-Old Woman With HER2+ Metastatic Breast Cancer and Brain Metastases: Optimal Treatment Approaches
EP. 9: Exploring the Latest Updates from the HER2CLIMB Trial Evaluating Tucatinib in Patients with Brain Metasteses
EP. 10: Managing Brain Metastases in HER2+ Metastatic Breast Cancer: Clinical Trial Data and Multidisciplinary Approaches
EP. 11: Evolving Treatment Paradigm in HER+ Breast Cancer: Future Directions

Related Content:

My Treatment Approach: HER2+ Breast CancerMemorial Sloan Kettering Cancer Center University of Illinois Cancer CenterUT Southwestern Harold C. Simmons Comprehensive Cancer Center Breast CancerInsights
Ongoing Research Could Help Define the Role of Immunotherapy in Earlier-Stage HCC
Dr O’Regan on Sequencing Considerations in Advanced HR+ Breast Cancer
STK-478 May Be an Effective, Tolerable Treatment Alternative in PIK3CA-Mutant Breast and Gynecologic Cancers